In colorectal cancer (CRC), therapy targeting the MAPK pathway is undermined by negative feedback, which results in increased sensitivity of the EGF receptor and consequently leads to the reactivation of both MAPK and AKT signaling pathways6,7. The gene discussed is AKT1; the disease is colorectal carcinoma.